Mercedes
Garayoa Berrueta
Investigadora desde 2011
Publicacións (34) Publicacións de Mercedes Garayoa Berrueta
2024
-
Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands
International Journal of Molecular Sciences, Vol. 25, Núm. 9
2021
-
Bone marrow mesenchymal stromal cells in multiple myeloma: Their role as active contributors to myeloma progression
Cancers, Vol. 13, Núm. 11
-
Immune system alterations in multiple myeloma: Molecular mechanisms and therapeutic strategies to reverse immunosuppression
Cancers, Vol. 13, Núm. 6, pp. 1-26
-
Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma
Cells, Vol. 10, Núm. 3
-
Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease
Nature Communications, Vol. 12, Núm. 1
2020
-
Filanesib for the treatment of multiple myeloma
Expert Opinion on Investigational Drugs, Vol. 29, Núm. 1, pp. 5-14
-
Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma
Haematologica
-
Protein translation inhibition is involved in the activity of the pan-pim kinase inhibitor pim447 in combination with pomalidomide-dexamethasone in multiple myeloma
Cancers, Vol. 12, Núm. 10, pp. 1-20
2019
-
Biological Background of Resistance to Current Standards of Care in Multiple Myeloma
Cells, Vol. 8, Núm. 11
-
Dihydropyrimidine-2-thiones as Eg5 inhibitors and L-type calcium channel blockers: Potential antitumour dual agents
MedChemComm, Vol. 10, Núm. 9, pp. 1589-1598
2017
-
Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair
Journal of Hematology and Oncology, Vol. 10, Núm. 1
-
Synergistic DNA-damaging effect in multiple myeloma with the combination of zalypsis, bor tezomib and dexamethasone
Haematologica, Vol. 102, Núm. 1, pp. 168-175
-
The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma
Haematologica, Vol. 102, Núm. 12, pp. 2113-2124
-
The novel pan-PIM kinase inhibitor, PIM447, displays dual antimyeloma and bone-protective effects, and potently synergizes with current standards of care
Clinical Cancer Research, Vol. 23, Núm. 1, pp. 225-238
2016
-
Effects of IL-8 Up-Regulation on Cell Survival and Osteoclastogenesis in Multiple Myeloma
American Journal of Pathology, Vol. 186, Núm. 8, pp. 2171-2182
2015
-
In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone
Leukemia, Vol. 29, Núm. 3, pp. 705-714
2014
-
Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell lines
PLoS ONE, Vol. 9, Núm. 3
-
Preclinical activity of the oral proteasome inhibitor mln9708 in myeloma bone disease
Clinical Cancer Research, Vol. 20, Núm. 6, pp. 1542-1554
-
Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: Implications in myeloma progression and myeloma bone disease
Oncotarget, Vol. 5, Núm. 18, pp. 8284-8305
2013
-
Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile
Blood, Vol. 122, Núm. 22, pp. 3591-3598